, and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.
The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.
Unless Specifically, while a graduate student and postdoctoral fellow at UTSW, Dr. Simmons manipulated results of cytotoxic T-lymphocyte (CTL) assays by adding predetermined amounts of radioactivity to scintillation counting vials rather than carrying out the assays as claimed.
As a result of falsifying these assays over a minimum of five years, none of Dr. Simmons research can be considered reliable and the publications identified below have been, or soon will be, retracted or corrected. The falsified research also was reported in the 1 R01 AI42860-01 grant application, ''A new MHC locus influencing class I peptide display.'' Additionally, Dr. Simmons was responsible for falsifying Figure 3 published in J. Immunol. 159:2750 Immunol. 159: -2759 Immunol. 159: , 1997 , by substituting preparations of chemically synthesized oligopeptide for natural peptides obtained from T cells isolated from B27 transgenic rats. These actions adversely and materially affected the laboratory's ongoing research into the role that human histocompatibility leukocyte antigens play in the development of disease.
The publications affected are: • Simmons, W.A., Leong, L.Y., Satumtira, N., Butcher, G.W., Howard, J.C., Richardson., J.A., Slaughter, C.A., Hammer, R.F., & Taurog, J.D. ''Rat MHClinked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease.'' J. Immunol. 156:1661 Immunol. 156: -1667 Immunol. 156: , 1996 (being retracted).
• Simmons, W.A., Roopenian, D.C., Summerfield, S.G., Jones, R.C., Galocha, B., Christianson, G.J., Maika, S.D., Zhou, M., Gaskell, S.J., Bordoli, R.S., Ploegh, H.L., Slaughter, C.A., Lindahl, K.F., Hammer, R.E., & Taurog, J.D. ''A new MHC locus that influences class I peptide presentation.'' Immunity 7:641-651, 1997 (retracted).
• Simmons, W.A., Taurog, J.D., Hammer, R.E., & Breban, M. ''Sharing of an HLA-B27-restricted H-Y antigen between rat and mouse. '' Immunogenetics 38:351-358, 1993 (retracted) .
• Zhou, M., Sayad, A., Simmons, W.A., Jones, R.C., Maika, S.D., Satumtira, N., Dorris, M.L., Gaskell, S.J., Bordoli, R.S., Sartor, R.B., Slaughter, C.A., Richardson, J.A., Hammer, R.F., & Taurog, J.D. ''The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats.'' J. Exp. Med. 188:877-886, 1998 (published erratum) .
Dr. Simmons has accepted the PHS findings and has entered into a Voluntary Exclusion Agreement with PHS in which he has voluntarily agreed for a period of five (5) (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations);
(2) to exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. The upcoming TRC meeting will be closed to the public in accordance with the Federal Advisory Committee Act (FACA), section 10(d) of 5 U.S.C., Appendix 2, implementing regulations, and procurement regulations, 41 CFR 101-6.1023 and 48 CFR section 315.604(d) . The discussions at this meeting of contract proposals submitted in response to the above-referenced RFP are likely to reveal proprietary information and personal information concerning individuals associated with the proposals. Such information is exempt from disclosure under the above-cited FACA provision that protects the free exchange of candid views, and under the procurement rules that prevent undue interference with Committee and Department operations. Rockville, Maryland, 20852, 301-594-1846. This notice is being published less than 15 days prior to the September 11th meeting due to the time constraints of reviews and funding cycles. 
Proposed Project
Youth Risk Behavior Survey-(0920-0258)-New-National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). The proposed project is the 2001 national schoolbased Youth Risk Behavior Survey. The purpose of this request is to renew OMB clearance to continue an ongoing biennial survey among high school students attending regular public, private, and Catholic schools in grades 9-12. The survey assesses priority heath risk behaviors related to the major preventable causes of mortality,
